26/10/2018
II Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations
Auditori del PRBB, de 9 a 17 hores
- 08:30-09:00 Registration
- 09:00-09:05 Welcome and opening. Joaquim Bellmunt
- 09:05-09:30 IO+IO Combinations. Christian Ottensmeier
09:30-11:00 Table 1. Immunotherapy in the clinic, focused on long term survival. Moderator - Joaquim Bellmunt
- 09:35-09:45 Melanoma. Ana Arance
- 09:50-10:05 Lung. Enriqueta Felip
- 10:10-10:25 Genitourinary. Alejo Rodríguez-vida
- 10:25-10:40 Other IO Indications. Maria Martínez
- 10:40-11:00 Discussion
- 11:00-11:20 Break coffee
11:00-13:40 Table 2. Biomarkers in immunotherapy. Moderator - Joan Albanell
- 11:20-11:35 PDL1 as a predictive biomarkers: pros and cons. Federico Rojo (TBC)
- 11:40-11:55 Predictive value of the Mutational load, neoantigens and clonal antigens. Somatic and germline genomic alterations. MSI. Beatriz Bellosillo
- 12:00-12:15 RNA Signatures as predictive biomarker. Aleix Prat (TBC)
- 12:20-12:35 Microbiome as predictor of benefit and toxicity. Giulana Magri
- 12:40-12:55 How to analyze genomic data for immunotherapy appliances. Abel González
- 13:00-13:15 TMB. Blood based biomarkers. Liquid biopsy. Aura Muntasell
- 13:20-13:35 Discussion
13:40-14:30 Lunch
14:30-16:40 Table 3. Futures perspectives on immunotherapy. Moderator - Edurne Arriola
- 14:30-14:45 Combination and sequencing: with radiation therapy, with
- chemotherapy and with targeted therapies. Josep Ma Piulats
- 14:50-15:05 Other immunotherapeutic approaches: new check point inhibitors
- and antibody drug conjugates and vaccines. Juan Martin Liberal
- 15:10-15:30 Discussion
15:30-16:10 Overcoming resistance to Immnonutherapy - Personalized Vaccines and other Approaches. Patrick Ott
16:15 Closing remarks
TECHNICAL SECRETARIAT
(The prior registration is required)
Aula Campus MAR
A/A Fernando Ochoa
T. 934 703 513
fochoa@meetingpharma.com
www.meetingpharma.com
Tots els actes
